



## Suggested Reading

---

- Kirkwood JM, Bender C, Agarwala S, et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. *J Clin Oncol*. 2002;20:3703-3718.
- Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. *J Natl Cancer Inst*. 2010;102(7):493-501.
- Weber J. Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. *Oncologist*. 2007;12(7):864-872.